| Execution period | 3 years |
|---|
NSE filing, NSE: TTKHLTCARE. Summary written from the filing by ALFA Finder's alert engine.
TTK Healthcare Ltd: key numbers
- Share price
- ₹1,019.00
- Market cap
- ₹1,440 Cr
- Revenue (annual)
- ₹857.3 Cr
- Net profit (annual)
- ₹65.68 Cr
- P/E (TTM)
- 19.5×Sector 21.7×
- Promoter holding
- 74.56%+0.00% QoQ
- FII holding
- 1.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TTK Healthcare Ltd
All →TTK Healthcare Board Meeting Date
TTK Healthcare will hold a board meeting on 30 October 2026 to consider unaudited financial results for the second quarter ended September 30, 2026. The trading window stays closed from 01 October to 01 November 2026.
TTK Healthcare Other Announcement
TTK Healthcare Limited has filed the Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
TTK Healthcare Merger & Restructuring Worth ₹256 Cr
TTK Healthcare completed the sale of its "EVA" and "Good Home" brands to Wipro Enterprises. The company received Rs. 256 crore in cash consideration.
- Value
- ₹256.0 Cr
TTK Healthcare Management Change
TTK Healthcare Ltd announced that its tax auditor, M/s Aiyar & Co., resigned effective August 26, 2026. The auditor cited eligibility issues regarding their peer review certificate.
TTK Healthcare Q1 FY27 Results: Net Profit ₹21.3 Cr, Up 63.8% YoY
TTK Healthcare Ltd reported revenue from operations of ₹257.6 Cr (+13.8% YoY) and net profit of ₹21.3 Cr (+63.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹21.3 Cr · +63.8% YoY
TTK Healthcare Board Meeting Date
TTK Healthcare has scheduled a board meeting for August 06, 2026, to approve the company's unaudited financial results for the first quarter ended June 30, 2026.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.